Q2 Earnings Estimate for HIMS Issued By Leerink Partnrs

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Equities researchers at Leerink Partnrs upped their Q2 2025 EPS estimates for Hims & Hers Health in a research note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.15 per share for the quarter, up from their prior estimate of $0.13. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health's Q3 2025 earnings at $0.17 EPS, FY2025 earnings at $0.69 EPS, FY2026 earnings at $0.79 EPS and FY2027 earnings at $1.20 EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same period in the previous year, the company earned $0.05 earnings per share. The company's revenue was up 110.7% compared to the same quarter last year.

HIMS has been the subject of several other reports. Citigroup reissued a "sell" rating and issued a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a research report on Tuesday. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price target for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Morgan Stanley reduced their target price on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Trading Up 18.9 %

NYSE HIMS opened at $49.80 on Wednesday. The company has a market cap of $11.06 billion, a P/E ratio of 113.19 and a beta of 1.84. Hims & Hers Health has a 1 year low of $11.64 and a 1 year high of $72.98. The company has a fifty day simple moving average of $32.39 and a 200 day simple moving average of $31.82.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Crewe Advisors LLC bought a new stake in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health during the 4th quarter worth $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In other news, insider Soleil Boughton sold 3,236 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $30.19, for a total transaction of $97,694.84. Following the transaction, the insider now owns 159,662 shares in the company, valued at approximately $4,820,195.78. This trade represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now owns 97,687 shares of the company's stock, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 650,500 shares of company stock valued at $25,790,311 in the last quarter. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.